1. What Is the Chronic Kidney Disease Market?
The Chronic Kidney Disease Market covers the medicines that slow the CKD progression, the cardiovascular complication prevention, and the anaemia and the mineral bone disease management. The declining kidney function creates these complications across the CKD stages G1 through G5 that the eGFR and the albuminuria categorisation defines for the 850 million people globally. The CKD arises from the diabetic nephropathy, the hypertension, the glomerulonephritis, and the polycystic kidney disease. CKD pharmacological management uses the RAAS blockade with the ACE inhibitor or the ARB that reduces the intraglomerular pressure and the proteinuria. The SGLT2 inhibitor dapagliflozin and empagliflozin achieved the 37 and 28 percent kidney composite event reduction in the DAPA-CKD and EMPA-KIDNEY trials for the non-diabetic and diabetic CKD patient. The nonsteroidal MRA finerenone demonstrated the cardiorenal protection for the diabetic CKD patient in the FIDELIO-DKD and FIGARO-DKD trials. The CKD market is advancing with the oral hypoxia-inducible factor prolyl hydroxylase inhibitors daprodustat, roxadustat, and vadadustat that the FDA approved for the CKD anaemia as the oral alternative to the ESA injection.
2. Chronic Kidney Disease Market Size & Forecast
3. Emerging Technologies
- SGLT2 inhibitor dapagliflozin DAPA-CKD Phase III demonstrated 39 percent reduction in the composite worsening kidney function, end-stage kidney disease, cardiovascular death, or all-cause death. The trial enrolled the diabetic and non-diabetic CKD patients with eGFR 25 to 75 mL/min. The EMPA-KIDNEY trial showed the 28 percent composite event reduction in the broader eGFR 20 to 45 population. The trials established the SGLT2 inhibitor as the universal CKD protective therapy independent of the diabetes that was the original indication.
- Finerenone FIDELIO-DKD and FIGARO-DKD nonsteroidal MRA demonstrated the 14 and 13 percent composite primary kidney outcome reduction and the 18 and 13 percent cardiovascular event reduction in the diabetic CKD patients. The drug provides the aldosterone receptor antagonism without the gynaecomastia and the hyperkalemia that the steroidal spironolactone and eplerenone create at higher rates. The non-steroidal selectivity achieves the improved tolerability.
- HIF-PHI daprodustat ASCEND-ND non-dialysis and ASCEND-D dialysis CKD anaemia Phase III demonstrated the haemoglobin non-inferiority to darbepoetin alfa with the oral administration that eliminates the subcutaneous injection. The drug provides the oral HIF prolyl hydroxylase inhibitor. The inhibitor stabilises HIF-1 alpha to increase the endogenous EPO production.
- Kidney Disease Improving Global Outcomes KDIGO CKD management guideline 2022 update incorporated the SGLT2 inhibitor and the GLP-1 agonist as the evidence-based treatments for the CKD patient with or without the diabetes. The update relied on the cardiorenal outcome trial evidence. The guideline expanded the CKD pharmacological management beyond the RAAS blockade.
Similar technologies are also transforming adjacent markets. Learn more in our Iga Nephropathy Market.
4. Key Market Opportunity
Substantial growth potential in the Chronic Kidney Disease market is SGLT2 inhibitor CKD indication market expansion driving prescribing in nephrology beyond endocrinology. AstraZeneca and Boehringer Ingelheim capturing growing CKD-indication SGLT2 prescribing reflects this paradigm-defining opportunity. A separate growth lever stems from finerenone non-steroidal MRA expansion and HIF-PHI oral anemia therapy growth. As SGLT2 CKD adoption proceeds and finerenone and HIF-PHI prescribing expands, the addressable opportunity is evolving from RAS-only CKD management toward multi-mechanism CKD pharmacotherapy.
5. Top Companies in the Chronic Kidney Disease Market
The following organisations hold leading positions in the Chronic Kidney Disease Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- AstraZeneca
- Boehringer Ingelheim
- Eli Lilly
- Bayer
- Novartis
- GSK
- Travere Therapeutics
- Akebia Therapeutics
- FibroGen
- Otsuka Pharmaceutical
- Bausch Health
- Vifor Pharma
- Calliditas Therapeutics
- Sanofi
- Amgen
6. Market Segmentation
The Chronic Kidney Disease Market is analysed across 4 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Drug Class | SGLT2 InhibitorNon-Steroidal MRAACEI/ARBHyperkalemia BinderESAHIF-PHI |
| By Stage | CKD 1-3CKD 4-5ESRD |
| By Etiology | DiabeticHypertensiveGlomerular |
| By Geography | North AmericaEuropeAsia PacificLatin AmericaMiddle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Chronic Kidney Disease Market trajectory over the forecast period:
DAPA-CKD 39 Percent and EMPA-KIDNEY 28 Percent Composite Kidney Event Reduction in Diabetic and Non-Diabetic CKD Has Established SGLT2 Inhibitor as the Universal CKD Protective Therapy Independent of Diabetes That Extends the Indication From the Original Glycaemic Control Target.KDIGO 2022 clinical practice guidelines classify SGLT2 inhibitors alongside RAAS blockade as mandatory background therapy for CKD patients with eGFR 20-45 mL/min/1.73m2 and UACR above 200 mg/g, representing a paradigm shift from guideline recommendation to mandatory standard where failure to prescribe requires documentation of clinical contraindication. The combined DAPA-CKD and EMPA-KIDNEY data enrolled approximately 17,000 CKD patients covering diabetic and non-diabetic aetiology including IgA nephropathy, focal segmental glomerulosclerosis, and polycystic kidney disease, establishing the renoprotective benefit across a broad CKD spectrum that includes conditions previously managed without specific pharmacotherapy. The commercial implication positions AstraZeneca and Boehringer Ingelheim and Eli Lilly as necessary therapeutic partners in nephrology practice, with per-patient annual prescribing of approximately USD 5,000 for the 8-10 million guideline-eligible patients in the US generating a multi-billion-dollar nephrology-directed SGLT2 inhibitor revenue stream.
Finerenone Nonsteroidal MRA FIDELIO-DKD and FIGARO-DKD 14 and 13 Percent Kidney and 18 and 13 Percent Cardiovascular Event Reduction Without the Gynaecomastia and High Hyperkalemia Rate of Steroidal MRA Has Established the Diabetic CKD Aldosterone Receptor Antagonism Standard.Travere Therapeutics's sparsentan demonstrated 49.8% UACR reduction from baseline in IgA nephropathy at 36 weeks in PROTECT compared with 15% for irbesartan, and 2-year histological data from the same trial demonstrated lower rates of fibrosis and inflammation on repeat biopsy in sparsentan-treated patients, establishing the first evidence of structural disease modification in IgA nephropathy beyond albuminuria suppression. The dual mechanism of endothelin-1 receptor blockade on mesangial cells combined with angiotensin receptor blockade achieves greater podocyte protection than either mechanism alone, and the FSGS efficacy data from DUET trial in focal segmental glomerulosclerosis establishes sparsentan's renoprotective mechanism across two distinct glomerular diseases with overlapping pathophysiology. The commercial positioning of sparsentan as a single-pill replacement for irbesartan plus an endothelin antagonist simplifies prescribing while achieving proteinuria reduction that separately justified Filspari approval based on interim data.
KDIGO 2022 CKD Guideline Incorporating SGLT2 Inhibitor and GLP-1 Agonist as Evidence-Based CKD Treatments With or Without Diabetes Has Expanded CKD Pharmacological Management Beyond RAAS Blockade to the Three-Pillar Programme That Cardiorenal Outcome Trials Established.Johnson and Johnson's zibotentan plus dapagliflozin combination is in Phase 3 ZENITH-CKD and ZENITH-FSGS trials testing whether endothelin receptor blockade adds to SGLT2 inhibitor renoprotection in CKD with residual proteinuria above guideline targets on RAAS blockade and SGLT2 inhibitor. Apellis Pharmaceuticals's pegcetacoplan C3 complement inhibitor is advancing in C3 glomerulopathy and membranous nephropathy where complement pathway dysregulation drives immune-complex deposition, addressing conditions where neither SGLT2 nor RAAS blockade effectively targets the pathogenic complement activation that destroys the glomerular filtration barrier. The combination of SGLT2-mandatory background therapy with condition-specific targeted therapy in rare glomerulonephritis represents the emerging treatment model where guidelines mandate non-specific renoprotection while regulatory approvals address the pathophysiology-specific mechanisms that determine disease trajectory.
For related market intelligence, see the Nephrology Drug Market.
8. Segmental Analysis
By drug class, the SGLT2 inhibitor segment dominated the Chronic Kidney Disease Market in 2025, as AstraZeneca's Farxiga and Boehringer Ingelheim and Eli Lilly's Jardiance demonstrated renal protection that anchored treatment, generating the fastest-rising branded revenue in the indication.
By etiology, the diabetic kidney disease segment is projected to register the highest growth rate through 2034, as Bayer's finerenone and GLP-1 agonists expand across the large diabetic population that represents the leading cause of chronic kidney disease progression to dialysis.
9. Regional Analysis
Regional demand patterns across the Chronic Kidney Disease Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America dominated the Chronic Kidney Disease Market in 2025, accounting for approximately 46% of global revenue, due to US premium pricing for SGLT2 inhibitors, finerenone, and CKD anemia therapy and the large CKD patient population. Moreover, SGLT2 inhibitor CKD adoption is most advanced in the US. In addition, finerenone prescribing for CKD with T2D is established. Regional dominance is attributed to this combination of pricing environment and CKD therapy expansion.
Highest CAGR Region
Asia Pacific is projected to register the highest CAGR in the Chronic Kidney Disease Market through 2034, driven by the very large CKD patient population in China, Japan, and India and expanding access to SGLT2 inhibitors, finerenone, and HIF-PHI oral anemia therapy through reimbursement growth. The region is also witnessing roxadustat broad adoption originating from China and Japan approvals. Moreover, CKD diagnosis and management infrastructure is expanding. The combination of these demand drivers and patient scale positions Asia Pacific for sustained growth outperformance through 2034.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology adoption trends and innovation tracking
- • Custom company profiling and benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country Trade Analysis
- • Country-level opportunity mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • List of Raw Material Suppliers
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Chronic Kidney Disease Market was valued at USD 15.70 Bn in 2025 and is projected to reach USD 45.31 Bn by 2034, growing at a CAGR of 12.5% over the 2026–2034 forecast period.
The Chronic Kidney Disease Market is projected to grow at a CAGR of 12.5% from 2026 to 2034.
North America dominated the Chronic Kidney Disease Market in 2025, accounting for approximately 46% of global revenue, due to US premium pricing for SGLT2 inhibitors, finerenone, and CKD anemia therapy and the large CKD patient population.
The leading companies in the Chronic Kidney Disease Market include AstraZeneca, Boehringer Ingelheim, Eli Lilly, Bayer, Novartis, GSK, Travere Therapeutics, Akebia Therapeutics, FibroGen, Otsuka Pharmaceutical, Bausch Health, Vifor Pharma, Calliditas Therapeutics, Sanofi, Amgen.
Dapa-ckd 39 percent and empa-kidney 28 percent composite kidney event reduction in diabetic and non-diabetic ckd has established sglt2 inhibitor as the universal ckd protective therapy independent of diabetes that extends the indication from the original glycaemic control target.
By drug class, the SGLT2 inhibitor segment dominated the Chronic Kidney Disease Market in 2025, as AstraZeneca's Farxiga and Boehringer Ingelheim and Eli Lilly's Jardiance demonstrated renal protection that anchored treatment, generating the fastest-rising branded revenue in the indication.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.